|1.||Curnow, R T: 2 articles (07/2001 - 02/2001)|
|2.||Fanger, M W: 2 articles (02/2001 - 02/2001)|
|3.||Fisher, J L: 2 articles (02/2001 - 02/2001)|
|4.||Guyre, P M: 2 articles (02/2001 - 02/2001)|
|5.||Kaufman, P A: 2 articles (02/2001 - 02/2001)|
|6.||Wallace, P K: 2 articles (02/2001 - 02/2001)|
|7.||Lewis, L D: 2 articles (02/2001 - 02/2001)|
|8.||Ernstoff, M S: 2 articles (02/2001 - 02/2001)|
|9.||Wong, J: 1 article (02/2007)|
|10.||Ritchie, D: 1 article (02/2007)|
09/15/1997 - "These in vitro data suggest that targeting tumor cells to Fc gammaRI with MDX-H210 may be an effective treatment for malignancies that overexpress HER2/neu. "
09/01/2003 - "In a solid tumor model, tumor growth was inhibited in Tg mice treated with a combination of MDX-H210 and CpG B. "
09/01/2003 - "In vitro CpG B also enhanced ADCC of HER-2/neu-expressing tumor cells by the FcgammaRI-directed bispecific antibody MDX-H210 using hFcgammaRI-positive effector cells. "
11/01/1997 - "Antitumor effects have been seen in response to MDX-H210 administration; these include 1 partial, 2 minor, and 1 mixed tumor response; 15 protocol-defined stable disease responses have occurred. "
09/15/1997 - "Therefore, tumor cells bound with MDX-H210 can be selectively recognized by effector cells with cytotoxic potential. "
02/01/2007 - "We describe the use of two methods of cell labelling for tracking the destination of autologous-derived macrophage activated killer (MAK) cells linked to the bi-specific antibody MDX-H210 delivered either by intravenous (i.v.) or intraperitoneal (i.p.) injection in ten patients with peritoneal relapse of epithelial ovarian carcinoma. "
12/15/2003 - "A phase I study of the bispecific antibody MDX-H210 in combination with granulocyte colony-stimulating factor (G-CSF) was performed in stage IV breast carcinoma patients, overexpressing HER-2/neu. "
07/20/2001 - "GM-CSF and MDX-H210 is active in hormone refractory prostate carcinoma with acceptable toxicity; further studies are warranted."
|3.||Breast Neoplasms (Breast Cancer)
04/01/1999 - "A phase I study of escalating doses of humanized bispecific antibody (bsAb) MDX-H210 with granulocyte-colony-stimulating factor (G-CSF) was conducted in patients with metastatic breast cancer that overexpressed HER2/neu. "
12/15/2003 - "Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer."
11/01/1997 - "Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer."
|4.||Prostatic Neoplasms (Prostate Cancer)
07/20/2001 - "A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer."
07/20/2001 - "We report results in 25 patients with HER2+ advanced prostate cancer treated with the bispecific antibody MDX-H210 15 microg m(-2)by intravenous infusion plus GM-CSF 5 microg kg(-1)day(-1)by subcutaneous injection for 4 days repeated weekly for 6 weeks. "
|1.||Granulocyte Colony-Stimulating Factor (G-CSF)
|2.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|3.||Interferon-gamma (Interferon, gamma)
|4.||Recombinant Interferon-gamma (Interferon gamma, Recombinant)
|8.||IgG Receptors (Fc gamma RI)
|9.||Epidermal Growth Factor Receptor (EGF Receptor)